BRAINSTORM CELL THERAPEUTICS INC. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 9 rows, 9 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2011-01-23: Reporting owner ACCBT Corp.; Form 4; Security Right to Acquire Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2010-02-24: Reporting owner ACCBT Corp.; Form 4; Security Right to Acquire Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2009-10-28: Reporting owner ACCBT Corp.; Form 4; Security Right to Acquire Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2009-08-18: Reporting owner ACCBT Corp.; Form 4; Security Right to Acquire Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
BCLI insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2011-01-23 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,499,999 0 owned after | $0.12 exercise price | $49.50 | 2011-04-28 |
| 2010-02-24 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000,001 10,499,999 owned after | $0.12 exercise price | $90.00 | 2011-04-28 |
| 2009-10-28 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,916,667 12,500,000 owned after | $0.12 exercise price | $67.50 | 2011-04-28 |
| 2009-08-18 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +14,166,667 22,416,667 owned after | $0.12 exercise price | $15.75 | 2011-04-28 |
| 2008-09-08 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,125,000 8,250,000 owned after | $0.18 exercise price | $58.50 | 2011-04-28 |
| 2008-04-03 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,125,000 12,375,000 owned after | $0.18 exercise price | $85.50 | 2008-04-28 |
| 2007-11-12 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,125,000 16,500,000 owned after | $0.18 exercise price | $144.00 | 2007-11-16 |
| 2007-08-10 | ACCBT Corp. 10% Owner | 4 | Right to Acquire Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,875,000 20,625,000 owned after | $0.18 exercise price | $225.00 | 2007-08-17 |
| 2007-08-01 holding as of filing | ACCBT Corp. 10% Owner | 3 | Right to Acquire Common Stock Derivative · Direct | Holding | no price filed | 2007-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |